Geoffrey Craig Porges net worth and biography

Geoffrey Porges Biography and Net Worth

CFO of Schrödinger

Geoff Porges, MBBS., is Chief Financial Officer. He joined Schrödinger in 2022 to lead the company’s financial operations, investor relations and corporate affairs activities, and business development and strategic planning for the company’s proprietary pharmaceuticals and biopharmaceutical collaborations. Geoff joined Schrödinger from SVB Securities, where he was most recently vice chairman. From 2015 until 2022, he was senior managing director, director of therapeutics research and senior research analyst at SVB Securities and at Leerink prior to its acquisition by SVB Securities. In that capacity, he led the Leerink/SVB therapeutics research team and personally provided research coverage for established and emerging diversified biopharmaceutical companies. Prior to joining SVB Securities, he was the biotechnology research analyst at Alliance Bernstein for 13 years. Earlier in his career, Geoff held executive positions at BTG plc and Merck, including leading the commercialization of Merck’s human vaccines. Geoff earned his medical degree from the University of Sydney and trained in pediatric and internal medicine in Australia. He is also a graduate of Harvard Business School where he was a Baker Scholar.

What is Geoffrey Craig Porges' net worth?: The estimated net worth of Geoffrey Craig Porges is at least $694,384.24 as of March 3rd, 2025. Porges owns 27,544 shares of Schrödinger stock worth more than $694,384 as of April 17th. This net worth approximation does not reflect any other assets that Porges may own. Learn More about Geoffrey Craig Porges' net worth.
How do I contact Geoffrey Craig Porges?: The corporate mailing address for Porges and other Schrödinger executives is 120 WEST 45TH STREET 17TH FLOOR, NEW YORK NY, 10036. Schrödinger can also be reached via phone at 212-295-5800 and via email at christina.tartaglia@sternir.com. Learn More on Geoffrey Craig Porges' contact information.
Has Geoffrey Craig Porges been buying or selling shares of Schrödinger?: Geoffrey Craig Porges has not been actively trading shares of Schrödinger in the last ninety days. Most recently, Geoffrey Craig Porges sold 5,491 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $21.76, for a transaction totalling $119,484.16. Following the completion of the sale, the chief financial officer now directly owns 27,544 shares of the company's stock, valued at $599,357.44. Learn More on Geoffrey Craig Porges' trading history.
Who are Schrödinger's active insiders?: Schrödinger's insider roster includes Robert Abel (Insider), Karen Akinsanya (Insider), Margaret Dugan (Insider), Jenny Herman (SVP), Rosana Kapeller-Libermann (Director), Joel Lebowitz (CFO), Kenneth Lorton (COO), Geoffrey Porges (CFO), David Shaw (Major Shareholder), Yvonne Tran (EVP), and Jorg Weiser (Director). Learn More on Schrödinger's active insiders.
Are insiders buying or selling shares of Schrödinger?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 23,745 shares worth more than $566,285.41. The most recent insider tranaction occured on April, 14th when insider Karen Akinsanya sold 16,723 shares worth more than $419,580.07. Insiders at Schrödinger own 8.6% of the company. Learn More about insider trades at Schrödinger.
Information on this page was last updated on 4/14/2025.

Geoffrey Craig Porges Insider Trading History at Schrödinger

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2025	Sell	5,491	$21.76	$119,484.16	27,544

Geoffrey Craig Porges Buying and Selling Activity at Schrödinger

Schrödinger Company Overview

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Today's Range

Now: $25.30

$24.57

$25.30

50 Day Range

MA: $21.98

$17.97

$26.54

2 Week Range

Now: $25.30

$16.60

$28.47

Volume

314,962 shs

Average Volume

819,278 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77